- Home
- ACDC vs AUPH Comparison
ACDC vs AUPH Comparison
Compare ACDC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACDC | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.6M | 1.6B |
| IPO Year | 2022 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ACDC | AUPH |
|---|---|---|
| Price | $4.21 | $15.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.83 | ★ $17.25 |
| AVG Volume (30 Days) | 918.8K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $1,960,000,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ N/A | $27.81 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $3.08 | $6.55 |
| 52 Week High | $10.70 | $16.54 |
Technical Indicators
Market Signals| Indicator | ACDC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 46.41 |
| Support Level | $3.68 | $14.82 |
| Resistance Level | $4.37 | $15.98 |
| Average True Range (ATR) | 0.21 | 0.40 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 79.14 | 34.59 |
Price Performance
Historical ComparisonAbout ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.